Search results for "AGENT"

showing 10 items of 8904 documents

Cytomegalovirus Pneumonia: A Possible Cause of Death in Patients With Crohn's Disease

2013

.

medicine.medical_specialtyCrohn's diseaseGastrointestinal agentCytomegalovirus pneumoniaHepatologyCrohn diseasebusiness.industryGastroenterologymedicine.diseaseCytomegalovirus Cytomegalovirus Infections ColitisGastroenterologyCytomegalovirus pneumonia Crohn’s diseaseAntibodies monoclonalInternal medicinemedicineIn patientbusinessCause of deathAmerican Journal of Gastroenterology
researchProduct

MORBILIDAD PSÍQUICA, EXISTENCIA DE DIAGNÓSTICO Y CONSUMO DE PSICOFÁRMACOS. DIFERENCIAS POR COMUNIDADES AUTÓNOMAS SEGÚN LA ENCUESTA NACIONAL DE SALUD …

2010

Background: Most of the studies on sychological distress in Spain have been conducted in small geographical areas or specific population groups. However, there are no studies that provide representative data for each Autonomous Community (AC). The objectives of this paper are to determine, both in Spain and in the AC, the prevalence of psychological distress, diagnosis, use of psychoactive medication, social support and self-perceived health, as well as to study the association between psychological distress and the rest of the variables. Methods: Cross-sectional study, using data from the 2006 National Health Survey, that was completed by 29,478 persons. Variables studied: sociodemographic…

medicine.medical_specialtyCross-sectional study:Psychiatry and Psychology::Mental Disorders [Medical Subject Headings]TerapéuticaPrevalencelcsh:MedicineTherapeuticsEncuestas de Atención de la SaludHealth Services Accessibility:Health Care::Environment and Public Health::Public Health::Epidemiologic Methods::Data Collection::Health Care Surveys [Medical Subject Headings]Salud mentalSocial supportDiagnosisAccesibilidad a los servicios de saludEpidemiologyHealth carePrevalencemedicineMedical prescriptionPsychiatryTerapeúticaMental disorder diagnosis:Health Care::Health Care Quality Access and Evaluation::Delivery of Health Care::Health Services Accessibility [Medical Subject Headings]:Geographicals::Geographic Locations::Europe::Spain [Medical Subject Headings]business.industryDiagnósticolcsh:Public aspects of medicinelcsh:Rlcsh:RA1-1270General Medicine:Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Central Nervous System Agents::Psychotropic Drugs [Medical Subject Headings]Mental healthMental HealthHealth Care SurveysSmall-Area Analysis:Health Care::Environment and Public Health::Public Health::Epidemiologic Methods::Data Collection::Vital Statistics::Morbidity::Prevalence [Medical Subject Headings]PrevalenciabusinessRevista Española de Salud Pública
researchProduct

Spanish Consensus on the Prevention and Treatment of Pseudomonas aeruginosa Bronchial Infections in Cystic Fibrosis Patients

2014

Pseudomonas aeruginosa is the main pathogen in bronchopulmonary infections in cystic fibrosis (CF) patients. It can only be eradicated at early infection stages while reduction of its bacterial load is the therapeutic goal during chronic infection or exacerbations. Neonatal screening and pharmacokinetic/pharmacodynamic knowledge has modified the management of CF-patients. A culture based microbiological follow-up should be performed in patients with no infection with P. aeruginosa. At initial infection, inhaled colistin (0,5-2 MU/tid), tobramycin (300 mg/bid) or aztreonam (75 mg/tid) with or without oral ciprofloxacin (15-20 mg/kg/bid, 2-3 weeks) are recommended. In chronic infections, trea…

medicine.medical_specialtyCystic Fibrosismedicine.drug_classAntibioticsAztreonammedicine.disease_causeCystic fibrosisCystic fibrosischemistry.chemical_compoundInternal medicinemedicineTobramycinHumansPseudomonas InfectionsIntensive care medicinebusiness.industryPseudomonas aeruginosaGeneral Medicinemedicine.diseaseAntibiotic treatmentAnti-Bacterial AgentsCiprofloxacinChronic infectionchemistryChronic DiseasePseudomonas aeruginosaDisease ProgressionColistinbusinessBronchial infectionmedicine.drugArchivos de Bronconeumología (English Edition)
researchProduct

Ultrastructural evidence for protection of the outer hair cells of the inner ear during intense noise exposure by application of the organic calcium …

1999

Outer hair cells could be protected during intense noise exposure by the application of the calcium channel blocker diltiazem given before and after noise treatment. After various experimental approaches, the ultrastructural morphology was analysed for the different animal populations in the basal part of the second turn of the cochlea, which was the most destroyed area after an acute noise trauma caused by a gun shot (sound pressure at the ear drum 156 dB, frequency maximum between 4 and 6 kHz). Compared to untreated control specimens (experimental animal group I), the outer hair cells in the basal part of the second turn of the cochlea were mostly destroyed without any diltiazem applicati…

medicine.medical_specialtyCytoplasmmedicine.drug_classmedicine.medical_treatmentGuinea PigsCalcium channel blockerAntiarrhythmic agentDiltiazemInternal medicinemedicineAnimalsInner earDiltiazemCochleaChemistryCalcium Channel BlockersDisease Models AnimalHair Cells Auditory OuterMicroscopy Electronmedicine.anatomical_structureEndocrinologyOtorhinolaryngologyHearing Loss Noise-InducedEar InnerAcute DiseaseUltrastructureBiophysicsAudiometry Pure-ToneHair cellNoiseNoise (radio)medicine.drugORL; journal for oto-rhino-laryngology and its related specialties
researchProduct

Safety of Topical Non-steroidal Anti-Inflammatory Drugs in Osteoarthritis: Outcomes of a Systematic Review and Meta-Analysis

2019

Objective We aimed to assess the safety of topical non-steroidal anti-inflammatory drugs (NSAIDs) in the management of osteoarthritis (OA) in a systematic review and meta-analysis of randomized, placebo-controlled trials. Methods A comprehensive literature search was undertaken in the MEDLINE, Cochrane Central Register of Controlled Trials (CENTRAL), and Scopus electronic databases. Randomized, double-blind, placebo-controlled, parallel-group trials that assessed adverse events (AEs) with topical NSAIDs in patients with OA were eligible for inclusion. Authors and/or study sponsors were contacted to obtain the full report of AEs. The primary outcomes were overall severe and serious AEs, as w…

medicine.medical_specialtyDICLOFENAC SODIUM GELDiclofenacDrug-Related Side Effects and Adverse ReactionsMedDRAVEHICLE TDT 064MEDLINEOsteoarthritisKNEE OSTEOARTHRITISAdministration CutaneousPlaceboLONG-TERM USE03 medical and health sciencesDOUBLE-BLIND0302 clinical medicinePharmacotherapyInternal medicineOsteoarthritisHumansMedicinePharmacology (medical)030212 general & internal medicineAdverse effectRandomized Controlled Trials as Topicbusiness.industryAnti-Inflammatory Agents Non-SteroidalTRANSFERSOME GELOdds ratiomedicine.diseaseEFFICACYRANDOMIZED CLINICAL-TRIALORAL CELECOXIBTreatment OutcomeMeta-analysisSystematic ReviewGeriatrics and Gerontologybusiness030217 neurology & neurosurgeryTASK-FORCE
researchProduct

A Decision Support Tool for Appropriate Glucose-Lowering Therapy in Patients with Type 2 Diabetes

2015

Contains fulltext : 152084.pdf (Publisher’s version ) (Open Access) BACKGROUND: Optimal glucose-lowering therapy in type 2 diabetes mellitus requires a patient-specific approach. Although a good framework, current guidelines are insufficiently detailed to address the different phenotypes and individual needs of patients seen in daily practice. We developed a patient-specific decision support tool based on a systematic analysis of expert opinion. MATERIALS AND METHODS: Based on the American Diabetes Association (ADA)/European Association for the Study of Diabetes (EASD) 2012 position statement, a panel of 12 European experts rated the appropriateness (RAND/UCLA Appropriateness Method) of tre…

medicine.medical_specialtyDecision support systemEndocrinology Diabetes and Metabolism[SDV]Life Sciences [q-bio]MEDLINEType 2 diabetesComorbidityHypoglycemiaGlucagon-Like Peptide-1 ReceptorBody Mass IndexEndocrinologyLife ExpectancyClinical ProtocolsInternal medicineHealth careReceptors GlucagonMedicineHumansHypoglycemic AgentsInsulinPrecision MedicineIntensive care medicineExpert TestimonyReimbursementComputingMilieux_MISCELLANEOUSGlycated HemoglobinDipeptidyl-Peptidase IV InhibitorsPioglitazonebusiness.industryDrug SubstitutionType 2 Diabetes MellitusMetabolic Disorders Radboud Institute for Molecular Life Sciences [Radboudumc 6]Original ArticlesPrecision medicinemedicine.diseaseDecision Support Systems ClinicalHypoglycemiaMetformin3. Good healthEuropeMedical Laboratory TechnologyEndocrinologySulfonylurea CompoundsDiabetes Mellitus Type 2Drug Therapy CombinationThiazolidinedionesbusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct

Pulmonary embolism hotline 2012. Recent and expected trials.

2012

SummaryManagement of acute pulmonary embolism (PE) has advanced considerably in the past year, and progress is expected to continue in 2013. To help determine the optimal management strategy for normotensive patients with intermediate-risk PE, the Pulmonary Embolism Thrombolysis (PEITHO) study completed enrolment of 1006 patients with evidence of right ventricular dysfunction (by echocardiography or computed tomography) plus a positive troponin test. Patients have been randomised to thrombolytic treatment with tenecteplase versus placebo, and the effects on clinical end points (death or haemodynamic collapse) assessed at 7 and 30 days. The results are expected in spring 2013; long-term foll…

medicine.medical_specialtyDeep veinmedicine.medical_treatmentTenecteplase030204 cardiovascular system & hematology03 medical and health scienceschemistry.chemical_compound0302 clinical medicineFibrinolytic AgentsEdoxabanmedicineHumans030212 general & internal medicineRivaroxabanClinical Trials as TopicEvidence-Based Medicinebusiness.industryHematologyThrombolysismedicine.diseaseThrombosisPulmonary embolismSurgerymedicine.anatomical_structureTreatment OutcomechemistryAnesthesiaApixabanbusinessPulmonary Embolismmedicine.drugForecastingHamostaseologie
researchProduct

Serum TRACP 5b Is a Useful Marker for Monitoring Alendronate Treatment: Comparison With Other Markers of Bone Turnover

2005

We studied clinical performance of serum TRACP 5b and other bone turnover markers, including S-CTX, U-DPD, S-PINP, S-BALP, and S-OC, for monitoring alendronate treatment. TRACP 5b had higher clinical sensitivity, area under the ROC curve, and signal-to-noise ratio than the other markers. INTRODUCTION: The purpose of this study was to compare the clinical performance of serum TRACP 5b (S-TRACP5b) with that of other markers of bone turnover in the monitoring of alendronate treatment. MATERIALS AND METHODS: This double-blinded study included 148 healthy postmenopausal women that were randomly assigned into two groups: one receiving 5 mg alendronate daily (n=75) and the other receiving placebo …

medicine.medical_specialtyDeoxypyridinolineEndocrinology Diabetes and MetabolismAcid PhosphataseUrologyPlaceboBone resorptionBone remodelingchemistry.chemical_compoundDouble-Blind MethodOsteogenesisInternal medicinemedicineVitamin D and neurologyHumansOrthopedics and Sports MedicineVitamin DAlendronateBone Density Conservation AgentsReceiver operating characteristicbiologyTartrate-Resistant Acid Phosphatasebusiness.industryAlendronic acidMiddle AgedIsoenzymesPostmenopauseEndocrinologychemistryOsteocalcinbiology.proteinCalciumFemaleDrug MonitoringbusinessBiomarkersmedicine.drugJournal of Bone and Mineral Research
researchProduct

Current Pharmacological Treatment of Painful Diabetic Neuropathy: A Narrative Review.

2020

Background and Objectives: Distal symmetrical polyneuropathy (DSPN) is one of the most common chronic complications of diabetes mellitus. Although it is usually characterized by progressive sensory loss, some patients may develop chronic pain. Assessment of DSPN is not difficult, but the biggest challenge is making the correct diagnosis and choosing the right treatment. The treatment of DSPN has three primary objectives: glycemic control, pathogenic mechanisms, and pain management. The aim of this brief narrative review is to summarize the current pharmacological treatment of painful DSPN. It also summarizes knowledge on pathogenesis-oriented therapy, which is generally overlooked in many p…

medicine.medical_specialtyDiabetic neuropathyAdministration TopicalMEDLINEPregabalinReviewCochrane LibraryDiabetic Neuropathiespharmacological treatmentDiabetes mellitusMedicineHumansPain ManagementpainIntensive care medicinelcsh:R5-920business.industryDiabetes mellitus Neuropathy Pain Pharmacological treatment Administration Topical Analgesics Opioid Anticonvulsants Antidepressive Agents Diabetic Neuropathies Humans Pain ManagementChronic painGeneral Medicinemedicine.diseaseAntidepressive AgentsAnalgesics OpioidNeuropathic paindiabetes mellitusAnticonvulsantsneuropathylcsh:Medicine (General)businessPolyneuropathymedicine.drugMedicina (Kaunas, Lithuania)
researchProduct

Cardiovascular imaging in the diagnosis and monitoring of cardiotoxicity: cardiovascular magnetic resonance and nuclear cardiology

2016

Chemotherapy-induced cardiotoxicity (CTX) is a determining factor for the quality of life and mortality of patients administered potentially cardiotoxic drugs and in long-term cancer survivors. Therefore, prevention and early detection of CTX are highly desirable, as is the exploration of alternative therapeutic strategies and/or the proposal of potentially cardioprotective treatments. In recent years, cardiovascular imaging has acquired a pivotal role in this setting. Although echocardiography remains the diagnostic method most used to monitor cancer patients, the need for more reliable, reproducible and accurate detection of early chemotherapy-induced CTX has encouraged the introduction o…

medicine.medical_specialtyDiagnostic methodspositron emission tomographycardiotoxicityEarly detectionAntineoplastic Agents030204 cardiovascular system & hematologynuclear cardiologyVentricular Function Left030218 nuclear medicine & medical imagingAntineoplastic Agent03 medical and health sciencescardiovascular magnetic resonance0302 clinical medicineQuality of lifeNeoplasmsInternal medicineEarly DiagnosimedicineHumanscardiotoxicity; cardiovascular magnetic resonanceCardiotoxicitymedicine.diagnostic_testbusiness.industryMyocardiumcardiotoxicity; cardiovascular magnetic resonance; nuclear cardiology; positron emission tomography; Antineoplastic Agents; Cardiotoxicity; Echocardiography; Humans; Neoplasms; Quality of Life; Early Diagnosis; Magnetic Resonance Imaging; Positron-Emission TomographyCancerMagnetic resonance imagingGeneral Medicinemedicine.diseaseMagnetic Resonance ImagingOxygenEarly DiagnosisCardiovascular DiseasesPositron emission tomographyEchocardiographyPositron-Emission TomographyCardiologyQuality of Lifecardiotoxicity cardiovascular magnetic resonance nuclear cardiology positron emission tomographyNeoplasmCardiology and Cardiovascular MedicineCardiac magnetic resonancebusinessHuman
researchProduct